BG
EPIX

Bellevue Group’s ESSA Pharma EPIX Stock Holding History

Bellevue Group’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,879,583
Closed -$47.8M – 164
2024
Q3 		$47.8M Sell
7,879,583
-10,000
-0.1% -$54.9K 0.77% 33
2024
Q2 		$41.5M Hold
7,889,583
– – 0.67% 39
2024
Q1 		$67M Sell
7,889,583
-9,000
-0.1% -$78.6K 1.02% 26
2023
Q4 		$52.1M Hold
7,898,583
– – 0.8% 37
2023
Q3 		$24.4M Hold
7,898,583
– – 0.39% 69
2023
Q2 		$21.3M Hold
7,898,583
– – 0.3% 76
2023
Q1 		$23.5M Hold
7,898,583
– – 0.34% 73
2022
Q4 		$19.9M Buy
7,898,583
+2,000,000
+34% +$5.74M 0.26% 84
2022
Q3 		$10.7M Buy
5,898,583
+888,869
+18% +$2.34M 0.15% 97
2022
Q2 		$15.8M Sell
5,009,714
-25,100
-0.5% -$140K 0.22% 94
2022
Q1 		$31.1M Hold
5,034,814
– – 0.36% 80
2021
Q4 		$71.5M Hold
5,034,814
– – 0.74% 48
2021
Q3 		$40.3M Buy
5,034,814
+2,575,000
+105% +$40.9M 0.41% 77
2021
Q2 		$70.3M Buy
2,459,814
+634,000
+35% +$18.4M 0.69% 50
2021
Q1 		$53M Buy
+1,825,814
New +$42.4M 0.56% 58

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bellevue Group's EPIX Position: Q4 2024 in Review

Bellevue Group sold out of ESSA Pharma (EPIX) in Q4 2024, closing a stake of 7,879,583 shares — an estimated $47.8M sold.

Bellevue Group first reported a position in EPIX in Q1 2021 and held it in 15 quarters. The position peaked at $71.5M in Q4 2021. 46 funds tracked by Wall St. Rank hold EPIX as of Q4 2024.

  • Bellevue Group reported no remaining ESSA Pharma position as of Q4 2024 after selling out during the quarter.
  • Bellevue Group sold 7,879,583 ESSA Pharma shares in Q4 2024, an estimated $47.8M.
  • Bellevue Group first reported a position in ESSA Pharma in Q1 2021 and held it in 15 quarters.
  • Bellevue Group's ESSA Pharma position peaked at $71.5M in Q4 2021.
  • 46 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2024.

Based on Bellevue Group's 13F filing for Q4 2024, filed 14 Feb 2025.